

CSL's Core Interests for Collaboration

Dr Priscilla Hong
Manager
Research Innovation

CSL at a Glance

40+

Countries of operations around the world

US$13.3

Billion in annual revenue

US$5.1

Billion in R&D investments in the last 5 years to advance product pipeline

32,000+

Employees around the world

2000+

R&D employees

340+

Plasma collection centres across China, Europe and North America

Top 25 Biotech Companies of 2023

GEN Genetic Engineering & Biotechnology News

Rank	Company	Ticker Symbol	Market Cap (US$ Billion)
1	Novo Nordisk	NOVO-B (CPH)	371.64
2	Thermo Fisher Scientific	TMO (NASD)	210.51
3	Amgen	AMGN (NASD)	126.31
4	**CSL Ltd**	**CSL (ASX)**	**101.4 B**
5	Gilead Sciences Inc	GILD (NASD)	99.98
6	Vertex Pharmaceuticals	VRTX (NASD)	88.83
7	Regeneron Pharmaceuticals	REGN (NASD)	87.64
8	Daiichi Sankyo	4568 (TOKYO SE)	69.55
9	Moderna	MRAN (NASD)	50.56
10	Jiangsu Hengrui Medicine Co Ltd	600276 (SHSE)	46.31
11	Chugai Pharmaceutical	4519 (TOKYO SE)	45.86
12	Biogen	BIIB (NASD)	44.69
13	Lonza	LONN (SWX)	44.33
14	Samsung Biologics	207940 (KRX KE)	44.12
15	Agilent Technologies	A (NYSE)	40.08
16	Seagan	SGEN (NASD)	37.5
17	Illumina	ILMN (NASD)	30.79
18	WuXi App Tec	603259 (SSEC)	29.33
19	Sun Pharmaceutical Industries	SUNPHARMA (NSE)	28.73
20	BeiGene	BGNE (NASD);06160 (HKE); 688235 (STAR SSEC)	27.50

https://www.genengnews.com/industry-news/top-25-biotech-companies-of-2023/

CSL's Core Therapeutic Areas & Platforms



Capabilities from Discovery to Patients



Antibody Discovery and Protein Engineering

In vitro pharmacology



Animal Models of Disease

Toxicology & Product Development

Patients

R&D CAPABILITIES — **CLINICAL CAPABILITIES**

Protein production and purification



Analytical Biochemistry

Translational Medicine & Data Science

Phase I-III/Launch Manufacturing

CSL's Research Acceleration Initiative

Objective: to build relationships with entrepreneurial researchers and fastrack discovery of innovative medicines that address unmet needs

Why? Early collaborations with high quality academic partners are key to building a sustainable pipeline

CSL's RAI provides a differentiated approach to partnering:

- ✓ Up to USD $400,000 funding over 2 years
- ✓ CSL scientific champion assigned to each project
- ✓ Focused on early-stage projects
- ✓ Simple and fast 300-word initial application
- ✓ Clear and transparent timelines



CSL has invested in 30+ RAI partnerships since 2019



" Peerless experience – timely, transparent, actionable communication."

RAI 2023 participant
University of British Columbia

We had a stellar experience participating in the CSL RAI process. The information material, informational webinars, and access to the program team for Q&A was well received by our faculty and resulted in a great number of pre-proposal submissions. Likewise, the selection process was well executed, transparent, and timely.

RAI 2023 participant
University of Pittsburgh

"It has been a great pleasure to collaborate with our colleagues at CSL. The Research Acceleration Initiative (RAI) is an outstanding platform that helps bridging the academic world with industry."

RAI 2021 awardee
Justus-Liebig-Universität Giessen

" Well-designed, easy and clear process. Highly engaged and highly responsive to all questions and provided well-contemplated and customised feedback. Submission through web portal was easy."

RAI 2023 participant
University of Toronto

"Our university has already participated in RAI three times. As we appreciate the perfect organization and the transparent and reliable communication, we will be happy to participate further in this initiative."

RAI 2021 participant
Office for Research and Technology Transfer
Ludwig-Maximilians-Universität (LMU) München

"CSL Behring has proven to be an exceptional collaborator, fostering a scientifically focused partnership marked by open scientific exchange and generosity. Their extensive research expertise has consistently enriched our collaborative efforts, making the interaction with CSL Behring an indispensable asset to our joint projects."

RAI 2021 awardee
Klinikum der Universität München (KUM)

"I found the RAI application process to be smooth and relatively straightforward. In particular, the sharing session was very useful because it clearly indicated which areas CSL was interested in funding, thereby allowing me to focus my thoughts on them."

RAI 2022 awardee
Nanyang Technological University

"As a first time RAI applicant, I found the process very streamlined and straightforward. The types of projects CSL were looking for was made very clear, the process of submitting an application was easy and did not require excessive time or effort. Helpful feedback."

RAI 2023 participant
Auckland UniServices Ltd

"The CSL RAI application process was straight-forward, assisted by engaged and professional personnel. For researchers invited to present their work, the opportunity to address feedback from CSL and to refine the project was particularly valuable"

RAI 2023 participant
The University of Adelaide

SEVEN NEW CSL RESEARCH

7

ACCELERATION INITIATIVE AWARDEES ANNOUNCED

Dr Laurent Martinez
Institute of Cardiovascular and Metabolic Diseases (I2MC), IHU HealthAge, INSERM / University of Toulouse, France

Prof. Delphine Borgel
INSERM - APHP - Université Paris SACLAY, France

Prof. Denis Vivien
INSERM / Caen Normandie University Hospital, France

Research Director Benoit Salomon
INSERM / University of Toulouse, France

Assoc Prof. Tan Meng How
Nanyang Technological University, Singapore

Prof. Elisa Laurenti
University of Cambridge, United Kingdom

Prof. Leon Schulte
Philipps-Universität Marburg, Germany

Driven by Our Promise

CSL

Benefits of CSL's Research Acceleration Initiative

Collaborate
with one of the world's leading biotech companies

Publish with CSL
200+ publications with our collaborators since 2020

Funding
of up to $400,000 USD over 2 years

Access expertise
CSL scientific champion assigned to provide you with industry guidance

Recognition
Awardees may use title "CSL Research Acceleration Initiative Fellow"

Accelerate
the translation of your research into new therapies

Access global capabilities
in R&D, clinical, intellectual property, manufacturing and commercial

Demonstrate impact
of your research to funding bodies via industry collaboration

CSL 2024 Research Acceleration Initiative Process



No obligation for registered organizations to submit applications

No limitation on number of abstracts each registered organization can submit

What makes for a competitive proposal?

- ✓ Aligned with our focus areas and modalities (slides 30-37)
- ✓ Project is clearly defined (as opposed to a general overview of the applicant's research interests)
- ✓ Focused on a novel target or therapeutic candidate
- ✓ Clear differentiation of approach from competitors and current standard of care
- ✓ Research team has capacity and expertise to complete the bulk of the experimental work over the course of the program (with CSL guidance and support)
- ✓ If third party IP is required, ensure your research organization has secured all necessary rights to grant CSL an exclusive option to negotiate an exclusive, worldwide licence

Examples of activities funded in previous RAI partnerships

- ✓ Human target validation and translational studies using patient samples
- ✓ Mechanism of action studies for therapeutic candidates
- ✓ Benchmarking to provide proof-of-concept for the differentiation of novel therapeutics to standard-of- care or competing therapeutics in development
- ✓ Target validation using genetic knock-out/knock-in or tool compounds in preclinical disease models
- ✓ Characterization of therapeutic candidates (e.g. affinity, potency, selectivity, and developability)

What is involved for participating research organizations?

Abstracts

- Internal promotion of initiative (*CSL to provide flyer)*
- Promotion of CSL information sessions/webinars for interested researchers
- Provide abstract submission portal link to researchers
- Discuss proposals with interested scientists ahead of 300-word abstract submission deadline

Full Application

- Support shortlisted researchers with preparation of full proposal via CSL RAI application form
- Ensure no disclosure of confidential information prior to submission of applications to CSL

Confidential Presentations

- Facilitation of CDA
- Assist with scheduling of confidential presentations to CSL

Funding Outcome

- Contract negotiation
- Preparation of detailed research plan and budget in partnership with CSL

Connect CSL with the appropriate internal contact(s) for each stage of the process

Checklist for 2024 Research Acceleration Initiative

- Register your research organization by 15th Dec 2023 by emailing RAI@csl.com.au (NB: 2023 participants are automatically re-enrolled)
- Update your organization's primary contact details if required
- CSL will provide flyer with primary contact details for promotion within your research organizations
- CSL will provide the link to the online abstract submission portal
- CSL will provide you with invitations to information webinars to share with interested researchers – webinars will be held in Feb 2024
- Online portal opens for abstract submissions by researchers on 2nd Jan 2024 and closes on 27th Feb 2024

Immunology

Core interests for early stage partnering

Novel targets or best-in-class biologic therapeutics addressing:

1. B cell and plasma cell depletion or inhibition
2. Regulatory T cell stimulation & T cell modulation/tolerization
3. Inhibition of effector T cells or T follicular helper cells (e.g., immune checkpoint agonism or co-stimulatory antagonism)
4. Depletion/modulation of innate immune effector cells
5. Modulation of cytokines, chemokines, or TNF super family members, particularly approaches enabling multi-pathway inhibition

Autoimmune diseases:

Novel targets or biologic therapies for the treatment of Inflammatory Idiopathic Myopathies including Dermatomyositis, Primary Sjögren's Syndrome, Pemphigus Vulgaris and Bullous Pemphigoid

Alternatives to plasma-derived immunoglobulins

Next generation synthetic or recombinant solutions for generating immunoglobulins (i.e. not derived from human plasma)

Not of interest:

Target discovery campaigns or platforms, intracellular targets, complement inhibition

Hematology

Core interests for early stage partnering

Acute hemorrhage control and hemorrhagic stroke

1. Novel biologic therapies to treat and prevent acute hemorrhage (e.g. intracerebral hemorrhage (ICH), reversal of anti-coagulation/anti-platelet associated bleeding)
2. Novel biologic targets and therapies for the treatment of secondary brain injury in subarachnoid hemorrhage and ICH
3. Omics approaches for patient stratification and drug discovery

Acute thrombotic conditions (macro- and micro-circulation)

1. Novel biologic therapies for targeted fibrinolysis/thrombolysis in acute thrombosis (ischemic stroke, pulmonary embolism)
2. Novel biologic therapies to treat and prevent microvascular thrombosis and endotheliopathies (e.g. TMAs, APS and DIC).

Benign hematology adjacencies*

1. Novel biologic therapies for the treatment of anemias
2. Novel biologic therapies to treat bone marrow disorders

* excluding SCD

Respiratory

Core interests for early stage partnering

Idiopathic pulmonary fibrosis (IPF), pulmonary sarcoidosis and progressive pulmonary fibrosis (PPF)

1. Novel biologic therapies or target proposals derived from translational or biobank cohorts
2. Therapies targeted at reversing remodelling of fibrotic lung tissue
3. Multiomics-based approaches to target discovery

Community acquired pneumonia (CAP)-associated complications

(Acute Respiratory Distress Syndrome (ARDS), Sepsis, Acute kidney injury)

1. Novel biologic therapies or target proposals derived from translational or biobank cohorts
2. In Silico approaches for patient stratification to delineate CAP patients at risk for ARDS/Sepsis/AKI



Cardiovascular and Metabolic

Core interests for early stage partnering

Major Adverse Cardiovascular Event (MACE) prevention
Atherosclerotic plaque stabilization in severe disease

Rare lipid disorders
Novel targets or biologic therapies (including gene therapies) for rare lipid disorders e.g. homozygous familial hypercholesterolemia

Myocarditis
Novel targets or biologic therapies for myocarditis
Biomarker approaches for patient stratification

Inflammatory cardiomyopathies
Novel targets or biologic therapies for inflammatory cardiomyopathies



Nephrology and Transplant

Core interests for early stage partnering

Acute and chronic solid organ transplant rejection (kidney/lung) therapies

Novel biologic therapies or targets to prevent or treat acute and chronic solid organ transplant rejection of the kidney and lung

Chronic graft versus host disease (GvHD)

Novel biologic therapies for the treatment and prevention of chronic GvHD

Tolerance for organ transplant rejection

Novel biologic therapies for the induction of tolerance to prevent or treat organ transplant rejection



Vaccines

Core interests for early stage partnering

Respiratory vaccines

1. New antigenic targets (epitopes or combinations)
2. Methods (e.g. AI/machine learning) to predict respiratory viral evolution/pathogenicity to inform vaccine development

New vaccine targets

Development of novel targets/approaches for any disease

RNA delivery and therapeutics

1. RNA delivery, enhanced stability, route of administration and/or expression strategies
2. mRNA-encoded protein therapies encompassing cellular targeting technologies

Immune mechanisms

Understanding innate and adaptive responses to vaccines



Cell & Gene Therapy

Core interests for early stage partnering

Gene editing / genomics

1. Improve insertional editing efficiencies *in vivo*
2. Genetic elements enhancing regulation of cells of the immune system (e.g., promoters and enhancers)

In vivo Delivery

1. Delivering nucleic acid templates for insertional gene editing
2. Targeting moiety for HSCs

GT safety

Technologies that minimize SAEs from insertional gene editing

Areas not of interest

- Oncology (including hematological malignancies)
- Ex vivo cell therapy



Plasma Protein Research

Core interests for early stage partnering

Novel plasma therapeutic candidates

1. All diseases considered. Candidates aligned with CSL's therapeutic areas will be prioritized
2. CSL can provide native human plasma proteins (≥ µg/L plasma concentration) for preclinical proof-of-concept studies

Novel association of plasma protein function with disease

1. Based on healthy and patient clinical data sets, or
2. Access to patient data sets with corresponding clinical data to enable association studies to be performed

Novel methods for plasma protein purification

Protein purification systems capable of targeted purification from plasma with high purity at research scale (methods translatable to manufacturing scale will be prioritized)

RAI Agreement Guidance

Separate collaboration agreements will be negotiated for each project which reflect the nature of the project, nature of funding and support, and the contributions of both parties

Under these negotiated agreements, CSL will be granted certain rights of interest to the program results for further R&D and/or commercialization

Collaboration agreements will typically include the following terms (although CSL may propose other conditions depending on the nature of the project):

- *Research organization will generally own results arising under the project*
  - CSL would typically own any results which relate to proprietary CSL products or materials contributed to the project or may seek joint-ownership of results to which it has made a significant contribution (e.g. protein or antibody discovery and engineering activities).
  - The RAI is designed to accelerate the translation of novel discoveries made by research scientists – for proposals outside this scope, we may propose that projects be progressed outside the RAI
- *CSL will be granted an exclusive option to negotiate an exclusive, worldwide licence*
- *CSL supports publication of research outcomes*

Further details on agreement terms can be provided on request

RAI Eligibility

To be eligible to apply, researchers/clinicians must satisfy the following 2 conditions:

1. Be employed by a research organization registered to participate in the 2024 Research Acceleration Initiative

2. Submit a 300-word online abstract that is aligned with CSL's Therapeutic Areas and scientific Platforms:



Specific indications of focus within each TA are provided on slides 30-37.

RAI Abstract submission via online portal





Submission T&Cs on last slide

THANK YOU

Dr Priscilla Hong
Manager,
Research Innovation

Priscilla.Hong@csl.com.au

csl.com/csl-rai